The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Long-Chain ω-3 Fatty Acids for Indicated Prevention of Psychotic Disorders: A Randomized, Placebo-Controlled Trial
Open accessAbstract
CONTEXT: The use of antipsychotic medication for the prevention of psychotic disorders is controversial. Long-chain omega-3 (omega-3) polyunsaturated fatty acids (PUFAs) may be beneficial in a range of psychiatric conditions, including schizophrenia. Given that omega-3 PUFAs are generally beneficial to health and without clinically relevant adverse effects, their preventive use in psychosis merits investigation. OBJECTIVE: To determine whether omega-3 PUFAs reduce the rate of progression to first-episode psychotic disorder in adolescents and young adults aged 13 to 25 years with subthreshold psychosis. DESIGN: Randomized, double-blind, placebo-controlled trial conducted between 2004 and 2007. SETTING: Psychosis detection unit of a large public hospital in Vienna, Austria. PARTICIPANTS: Eighty-one individuals at ultra-high risk of psychotic disorder. INTERVENTIONS: A 12-week intervention period of 1.2-g/d omega-3 PUFA or placebo was followed by a 40-week monitoring period; the total study period was 12 months. MAIN OUTCOME MEASURES: The primary outcome measure was transition to psychotic disorder. Secondary outcomes included symptomatic and functional changes. The ratio of omega-6 to omega-3 fatty acids in erythrocytes was used to index pretreatment vs posttreatment fatty acid composition. RESULTS: Seventy-six of 81 participants (93.8%) completed the intervention. By study's end (12 months), 2 of 41 individuals (4.9%) in the omega-3 group and 11 of 40 (27.5%) in the placebo group had transitioned to psychotic disorder (P = .007). The difference between the groups in the cumulative risk of progression to full-threshold psychosis was 22.6% (95% confidence interval, 4.8-40.4). omega-3 Polyunsaturated fatty acids also significantly reduced positive symptoms (P = .01), negative symptoms (P = .02), and general symptoms (P = .01) and improved functioning (P = .002) compared with placebo. The incidence of adverse effects did not differ between the treatment groups. CONCLUSIONS: Long-chain omega-3 PUFAs reduce the risk of progression to psychotic disorder and may offer a safe and efficacious strategy for indicated prevention in young people with subthreshold psychotic states. Trial Registration clinicaltrials.gov Identifier: NCT00396643.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Only two studies had an overall low risk of bias 33,79 ; five had unclear risk [72][73][74][75][76] , and nine had high risk 30,31,36,37,39,41,77,78,81 .”
From Lack of evidence to favor specific preventive interventions in psychosis: a network meta‐analysis (2018) · cites this paper as [33]
In the citing paper
“Earlier studies that dominated the conclusions of some previous meta-analyses (e.g., the omega-3 trial 33 ) were likely false positives.”
From Lack of evidence to favor specific preventive interventions in psychosis: a network meta‐analysis (2018) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2022) · doi:10.1176/appi.books.9780890425787 · Cited by 23,476
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
van Os, J., Linscott, R. J., Myin-Germeys, I., Delespaul, P., & Krabbendam, L. (2009) · Psychological Medicine · doi:10.1017/s0033291708003814 · Cited by 2,343
Fish Intake, Contaminants, and Human Health: Evaluating the Risks and the Benefits
Mozaffarian, D., & Rimm, E. B. (2006) · JAMA · doi:10.1001/jama.296.15.1885 · Cited by 1,966
The Family History Method Using Diagnostic Criteria
Andreasen, N. C. (1977) · Archives of General Psychiatry · doi:10.1001/archpsyc.1977.01770220111013 · Cited by 1,903
The number needed to treat: a clinically useful measure of treatment effect
Cook, R. J., & Sackett, D. L. (1995) · BMJ · doi:10.1136/bmj.310.6977.452 · Cited by 1,885
Lingjærde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb10566.x · Cited by 1,705
Association Between Duration of Untreated Psychosis and Outcome in Cohorts of First-Episode Patients
Marshall, M., Lewis, S. W., Lockwood, A., Drake, R., Jones, P. B., & Croudace, T. J. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.9.975 · Cited by 1,595
Gueorguieva, R., & Krystal, J. H. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.3.310 · Cited by 1,529
Pantelis, C., Velakoulis, D., McGorry, P. D., Wood, S. J., John Suckling, A., Phillips, L., Yung, A. R., Bullmore, E. T., Brewer, W. J., Soulsby, B., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12323-9 · Cited by 1,309
Self-citationChildren's Self-Reported Psychotic Symptoms and Adult Schizophreniform Disorder
Poulton, R., Caspi, A., Moffitt, T. E., Cannon, M. D., Murray, R. M., & Harrington, H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.11.1053 · Cited by 1,139
McGorry, P. D., Yung, A. R., Phillips, L. J., Yuen, H. P., Francey, S., Cosgrave, E. M., Germano, D., Bravin, J., McDonald, T., Blair, A., et al. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.10.921 · Cited by 1,056
Self-citationPrabakaran, S., SWATTON, J. E., Ryan, M. M., Huffaker, S. J., Huang, J.-J., Griffin, J. L., Wayland, M. T., Freeman, T., Dudbridge, F., Lilley, K. S., et al. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001511 · Cited by 985
Joint modelling of longitudinal measurements and event time data
Henderson, R. (2000) · Biostatistics · doi:10.1093/biostatistics/1.4.465 · Cited by 919
McGorry, P. D., Hickie, I. B., Yung, A. R., Pantelis, C., & Jackson, H. J. (2006) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2006.01860.x · Cited by 919
Self-citationMorrison, A. P., French, P., Walford, L., Lewis, S. W., Kilcommons, A., Green, J., Parker, S., & Bentall, R. P. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.185.4.291 · Cited by 740
Omega-3 Fatty Acids: Evidence Basis for Treatment and Future Research in Psychiatry
Freeman, M. P., Hibbeln, J. R., Wisner, K. L., Davis, J. M., Mischoulon, D., Peet, M., Keck, P. E., Marangell, L. B., Richardson, A. J., Lake, J., et al. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1217 · Cited by 709
Prediction of psychosis. A step towards indicated prevention of schizophrenia.
Yung, A. R., Phillips, L., McGorry, P. D., McFarlane, C. A., Francey, S. M., Harrigan, S., Patton, G. C., & Jackson, H. J. (1998) · PubMed · Cited by 698
Self-citationPeet, M., & Horrobin, D. F. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.10.913 · Cited by 615
Prevalence of Psychotic Disorder and Community Level of Psychotic Symptoms
van Os, J., Hanssen, M., Bijl, R. V., & Vollebergh, W. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.7.663 · Cited by 567
McGlashan, T. H., Zipursky, R. B., Perkins, D., Addington, J., Miller, T., Woods, S. W., A. Hawkins, K., E. Hoffman, R., Preda, A., Epstein, I., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.5.790 · Cited by 556
Prabakaran, S., SWATTON, J. E., Ryan, M. M., Huffaker, S. J., Huang, J. T.-J., Griffin, J. L., Wayland, M. T., Freeman, T., Dudbridge, F., Lilley, K. S., et al. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001532 · Cited by 375
The membrane hypothesis of schizophrenia
Horrobin, D. F., Glen, A. I. M., & Vaddadi, K. S. (1994) · Schizophrenia Research · doi:10.1016/0920-9964(94)90043-4 · Cited by 340
Peet, M., Brind, J., Ramchand, C. N., Shah, S., & Vankar, G. K. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00083-9 · Cited by 329
Peet, M., & Horrobin, D. F. (2002) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(01)00048-6 · Cited by 329
Fenton, W. S., Hibbeln, J. R., & Knable, M. B. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00092-x · Cited by 328
Fenton, W. S., Dickerson, F., Boronow, J. J., Hibbeln, J. R., & Knable, M. B. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.12.2071 · Cited by 322
Impaired glutathione synthesis in schizophrenia: Convergent genetic and functional evidence
Gysin, R., Kraftsik, R., Sandell, J., Bovet, P., Chappuis, C., Conus, P., Deppen, P., Preisig, M., Ruiz, V., Steullet, P., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706778104 · Cited by 309
Emsley, R. A., Myburgh, C., Oosthuizen, P. P., & van Rensburg, S. J. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.9.1596 · Cited by 306
Dopamine activation of the arachidonic acid cascade as a basis for D1D2 receptor synergism
Piomelli, D., Pilon, C., Bruno Giros, A., Sokoloff, P., Martres, M., & Schwartz, J.-C. (1991) · Nature · doi:10.1038/353164a0 · Cited by 258
Cuijpers, P. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1385 · Cited by 217
Steullet, P., Neijt, H. C., Cuénod, M., & Do, K. Q. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2005.10.014 · Cited by 173
Neurotrophins enhance retinal pigment epithelial cell survival through neuroprotectin D1 signaling
Mukherjee, P. K., Marcheselli, V. L., Barreiro, S., Hu, J., Bok, D., & Bazan, N. G. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705949104 · Cited by 170
McGlashan, T. H. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.5.790 · Cited by 160
Ethyl-Eicosapentaenoic Acid in First-Episode Psychosis
Berger, G. E., & Proffitt, T. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1206 · Cited by 152
Self-citationPolyunsaturated fatty acid supplementation for schizophrenia
Irving, C. B., Mumby-Croft, R., & Joy, L. A. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001257.pub2 · Cited by 140
Ethyl-Eicosapentaenoic Acid in First-Episode Psychosis. A 1H-MRS Study
Berger, G. E., Wood, S. J., Wellard, R. M., Proffitt, T., McConchie, M., Amminger, G. P., Jackson, G. D., Velakoulis, D., Pantelis, C., & McGorry, P. D. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301628 · Cited by 116
Self-citationPACE: a specialised service for young people at risk of psychotic disorders
Yung, A. R., McGorry, P. D., Francey, S. M., Nelson, B., Baker, K., Phillips, L., Berger, G. E., & Amminger, G. P. (2007) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2007.tb01336.x · Cited by 104
Self-citationComparison of biochemical effects of statins and fish oil in brain: The battle of the titans
Farooqui, A. A., Ong, W., Horrocks, L. A., Chen, P., & Farooqui, T. (2007) · Brain Research Reviews · doi:10.1016/j.brainresrev.2007.09.004 · Cited by 100
Talbott, J. A. (2007) · Yearbook of Psychiatry and Applied Mental Health · doi:10.1016/s0084-3970(08)70423-7 · Cited by 92
McGorry, P. D., Yung, A. R., Bechdolf, A., & Amminger, G. P. (2008) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2007.9 · Cited by 85
Self-citationCohen, D., Deniau, E., Maturana, A., Tanguy, M., Bodeau, N., Labelle, R. J., Breton, J., & Guilé, J.-M. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002632 · Cited by 69
Polyunsaturated fatty acid supplementation for schizophrenia
Joy, C., Mumby-Croft, R., & Joy, L. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001257 · Cited by 45
Research works printed but not linked: 1
- First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. New York, NY: Biometrics Research, New York State Psychiatric Institute; 2002.
Cited by
Sorted by citations
Owen, M. J., Sawa, A., & Mortensen, P. B. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01121-6 · Cited by 1,870
Insel, T. R. (2010) · Nature · doi:10.1038/nature09552 · Cited by 1,783
Polyunsaturated fatty acids and their metabolites in brain function and disease
Bazinet, R. P., & Layé, S. (2014) · Nature reviews. Neuroscience · doi:10.1038/nrn3820 · Cited by 1,703
The Psychosis High-Risk State: A Comprehensive State-of-the-Art Review
Fusar-Poli, P., Borgwardt, S., Bechdolf, A., Addington, J., Riecher-Rössler, A., Schultze-Lutter, F., Keshavan, M., Wood, S., Ruhrmann, S., Seidman, L. J., et al. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.269 · Cited by 1,483
Self-citationPredicting Psychosis: Meta-analysis of Transition Outcomes in Individuals at High Clinical Risk
Fusar-Poli, P. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.1472 · Cited by 1,361
Metadata
- Authors
- Amminger, G. P., Schäfer, M. R., Papageorgiou, K., Klier, C. M., Cotton, S. M., Harrigan, S. M., Mackinnon, A., McGorry, P. D., & Berger, G. E.
- Affiliations
- Medical University of Vienna (AT)
- The University of Melbourne (AU)
- Clienia AG (CH)
- ORCID
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2010-02-01
- Volume
- 67
- Issue
- 2
- Pages
- 146
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2130372506
- Cited by
- 896
- References
- 45
- Citations by year
- 2026: 13 · 2025: 20 · 2024: 29 · 2023: 22 · 2022: 20 · 2021: 51 · 2020: 42 · 2019: 59 · 2018: 33 · 2017: 52 · 2016: 69 · 2015: 82 · 2014: 95 · 2013: 85 · 2012: 98
- FWCI
- 92.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Archives of General Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Stanley Medical Research Institute (03T-315)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- omega-3 polyunsaturated fatty acids, clinical high risk for psychosis, schizophrenia, adolescents and young adults, n-6/n-3 ratio, erythrocyte fatty acids, positive symptoms, negative symptoms, functional outcome, dietary supplementation, psychosis prevention, omega-3 deficiency
- MeSH terms
- Adolescent, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Female, Health Status, Humans, Male, Patient Acceptance of Health Care, Psychotic Disorders, Risk Factors, Schizotypal Personality Disorder, Severity of Illness Index, Fatty Acids, Omega-3, Treatment Outcome, Diagnostic and Statistical Manual of Mental Disorders, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
